Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best biotech stocks to buy according to Wall Street analysts. On ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Idorsia’s dual orexin receptor antagonist, the first and only drug of its kind approved in Europe for the treatment of ...

Merck spent $10bn on lung disease-focused biotech Verona Pharma in July, its biggest acquisition in two years, amid concerns ...

Applied’s lead candidate is a selective aldose reductase inhibitor called govorestat, an asset that failed to hit primary endpoints in late-stage trials for a progressive neuromuscular disease called ...

Seventy-three pharmaceutical, biotechnology and medical device companies from mainland China filed for IPOs in Hong Kong this year, a review by BioWorld found. In the second half of 2025, 43 new ...

With regulators across Asia-Pacific easing pathways for new therapies, Dimerix is positioning DMX-200 for one of the world’s ...

Ultragenyx Pharmaceutical stock reacts to shifting sentiment Ultragenyx Pharmaceutical (RARE) has been quietly recalibrating investor expectations, with the stock up about 10% over the past month even ...

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a merger with MindWave Innovations Inc, uniting Apimeds' late-stage, non-opioid pain-management biologic portfolio with MindWave's AI-d ...

In the northwest corner of Sioux Falls, an 80-acre campus opened its first building this year dedicated entirely to expanding ...

Dec 10 (Reuters) - French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma ...